Royalty Pharma plc (NASDAQ:RPRX)
| Market Cap | $30.48B+75.9% |
| Revenue (ttm) | $2.62B+11.4% |
| Net Income | $671.45M-12.2% |
| EPS | $1.53-13.1% |
| Shares Out | 445.27M |
| PE Ratio | 40.98 |
| Forward PE | 11.62 |
| Dividend | $0.94(1.37%) |
| Ex-Dividend Date | Nov 13, 2026 |
| Volume | 3,531,035 |
| Open | $68.17 |
| Previous Close | $67.72 |
| Day's Range | $67.95 - $68.83 |
| 52-Week Range | $37.31 - $70.37 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | $71.00(+3.73%) |
| Earnings Date | Feb 10, 2027 |
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating RPRX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 10, 2027Earnings report
$RPRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RPRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RPRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RPRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RPRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RPRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RPRX
| VXFVanguard Extended Market ETF | $339.19M |
| VFLOVictoryShares Free Cash Flow ETF | $246.09M |
| IWRiShares Russell Mid-Cap ETF | $120.18M |
| VYMVanguard High Dividend Yield ETF | $113.10M |
| IHEiShares U.S. Pharmaceuticals ETF | $81.87M |
| CGDGCapital Group Dividend Growers ETF | $81.49M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from RPRX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upgrades and earnings beat offset neutral conference appearances and comparison articles with mixed conclusions.
Recent Insider Activity
Insider Score Trend Over Time
-38.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| PBE | Invesco Biotechnology & Genome ETF | 5.55% |
| ELCF | Eventide Large Cap Focus ETF | 5.41% |
| PTNT | Corgi ETF Trust I - Corgi IP Licensing & Royalties ETF | 4.90% |
| IHE | iShares U.S. Pharmaceuticals ETF | 4.78% |
| ELCV | Eventide High Dividend ETF | 4.51% |
| ETDG | Eventide Dividend Growth ETF | 4.51% |
| BTAL | AGF U.S. Market Neutral Anti-Beta Fund | 4.27% |
| ADPV | Adaptiv Select ETF | 4.10% |
| TFGZ | Thornburg Focus Growth Fund | 3.50% |
| GFLW | Victory Portfolios II - Victoryshares Free Cash Flow Growth ETF | 3.15% |
| SAMM | Strategas Macro Momentum ETF | 2.95% |
| MVFD | Monarch Volume Factor Dividend Tree ETF | 2.76% |
Weight is the stock’s share of each fund’s holdings.
